Beyond Blood-Brain Barrier Crossing in Reperfusion-Era Ischemic Stroke: Interface-Matched Active-Entity Delivery and Translational Product Design
- 1Department of Neurology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, People’s Republic of China
- 2Department of Thoracic Surgery, Shenzhen People’s Hospital, Shenzhen, Guangdong, People’s Republic of China
Abstract
Reperfusion therapy has transformed acute ischemic stroke care, yet large-vessel recanalization does not ensure capillary reperfusion, preservation of the blood-brain barrier and neurovascular unit (BBB/NVU), or durable neurological recovery. Nanomedicine is still commonly judged by BBB crossing or ischemic-hemisphere accumulation, although vascular access, tissue viability, transport phenotype, thromboinflammation, and standard treatment change rapidly during the lifetime of a formulation. This narrative review proposes a conceptual framework that matches the reperfusion state and pathological interface to the compartment in which the therapeutically active entity must act. The framework is intended to organize preclinical evidence and generate testable translational hypotheses; it has not yet been clinically validated. Persistent occlusion may favor intravascular targets, whereas recanalization with no-reflow creates a distinct microvascular delivery problem. Early reperfusion injury may prioritize BBB/NVU stabilization, while later biological contexts may require selective immune, regenerative, or organelle-directed interventions. These contexts may coexist spatially, vary across vascular territories, and shift during treatment; they should therefore not be interpreted as a mandatory chronological sequence. We distinguish BBB crossing, controlled barrier modulation, and BBB/NVU repair as separate therapeutic tasks, and introduce transport attrition as a practical explanation for why sequential targeting, transcytosis, cellular uptake, endosomal escape, and organelle localization can yield little final active-entity exposure despite strong tissue imaging. Recent predominantly preclinical examples illustrate how thrombus-targeted rtPA systems, neutrophil-intercepting particles, NET-degrading polymersomes, lesion-targeted nanoplatforms, and mitochondrial nanomedicines may fit different delivery topologies. Translational credibility requires topology-resolved exposure, target engagement in viable tissue, hemocompatibility under antithrombotic treatment, state-appropriate models, function-linked manufacturing controls, and compatibility with thrombolysis and thrombectomy.
Related
- Navigating the Renal Bio–Nano Interface: Physicochemical Rules for Crossing Barriers and Cellular Transport
- DNA and mRNA Vaccines Against Hantaviruses: Antigen Design, Delivery Strategies and Translational Progress
- Hydrogel-Based BMP-2 Delivery for Bone Regeneration: From Material Control to Biological and Translational Evaluation
- Artificial intelligence and machine learning-guided bio-orthogonal engineering of smart soft polymeric nanocarriers for precision drug delivery and translational nanomedicine
- Advanced Drug Delivery in Pediatric Neurology: Developmental Barriers, Nanocarrier Strategies, and Translational Challenges.
BibTeX
@article{bu2026beyond,
title = {{Beyond Blood-Brain Barrier Crossing in Reperfusion-Era Ischemic Stroke: Interface-Matched Active-Entity Delivery and Translational Product Design}},
author = {Fan Bu and YuanYuan Cao and Fengjiao Chen and Yi Wen and Lile Xiong},
journal = {International Journal of Nanomedicine},
year = {2026},
month = oct,
doi = {10.2147/ijn.s650851},
url = {https://doi.org/10.2147/ijn.s650851},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Beyond Blood-Brain Barrier Crossing in Reperfusion-Era Ischemic Stroke: Interface-Matched Active-Entity Delivery and Translational Product Design
AU - Fan Bu
AU - YuanYuan Cao
AU - Fengjiao Chen
AU - Yi Wen
AU - Lile Xiong
PY - 2026
DA - 2026/10/27
JO - International Journal of Nanomedicine
DO - 10.2147/ijn.s650851
UR - https://doi.org/10.2147/ijn.s650851
AB - Reperfusion therapy has transformed acute ischemic stroke care, yet large-vessel recanalization does not ensure capillary reperfusion, preservation of the blood-brain barrier and neurovascular unit (BBB/NVU), or durable neurological recovery. Nanomedicine is still commonly judged by BBB crossing or ischemic-hemisphere accumulation, although vascular access, tissue viability, transport phenotype, thromboinflammation, and standard treatment change rapidly during the lifetime of a formulation. This narrative review proposes a conceptual framework that matches the reperfusion state and pathological interface to the compartment in which the therapeutically active entity must act. The framework is intended to organize preclinical evidence and generate testable translational hypotheses; it has not yet been clinically validated. Persistent occlusion may favor intravascular targets, whereas recanalization with no-reflow creates a distinct microvascular delivery problem. Early reperfusion injury may prioritize BBB/NVU stabilization, while later biological contexts may require selective immune, regenerative, or organelle-directed interventions. These contexts may coexist spatially, vary across vascular territories, and shift during treatment; they should therefore not be interpreted as a mandatory chronological sequence. We distinguish BBB crossing, controlled barrier modulation, and BBB/NVU repair as separate therapeutic tasks, and introduce transport attrition as a practical explanation for why sequential targeting, transcytosis, cellular uptake, endosomal escape, and organelle localization can yield little final active-entity exposure despite strong tissue imaging. Recent predominantly preclinical examples illustrate how thrombus-targeted rtPA systems, neutrophil-intercepting particles, NET-degrading polymersomes, lesion-targeted nanoplatforms, and mitochondrial nanomedicines may fit different delivery topologies. Translational credibility requires topology-resolved exposure, target engagement in viable tissue, hemocompatibility under antithrombotic treatment, state-appropriate models, function-linked manufacturing controls, and compatibility with thrombolysis and thrombectomy.
SN - 1176-9114
SN - 1178-2013
ER -